Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMYLOVR)

Drug Name
Aciclovir Drug Info
Synonyms
acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir
Therapeutic ClassAntiviral Agents
Cross-matching ID
PubChem CID
135398513
ChEBI ID
CHEMBL184
CAS Number
CAS 59277-89-3
TTD Drug ID
D0B5MP
VARIDT Drug ID
DR00325
ACDINA Drug ID
D00013

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Valine, leucine and isoleucine degradation -1.61 4.97e-2 42/48 (87.5%) HIBCH;ALDH1B1;DBT;...
PPAR signaling pathway -1.62 4.85e-2 66/74 (89.19%) LPL;ACSL6;GK;...
Alzheimer disease -1.64 4.34e-2 279/369 (75.61%) ATG101;FZD5;MAPK8;...
Folate biosynthesis -1.65 4.04e-2 23/26 (88.46%) FPGS;QDPR;PCBD1;...
Pertussis -1.67 3.11e-2 64/76 (84.21%) RHOA;NFKB1;CXCL5;...
Rheumatoid arthritis -1.67 3.19e-2 78/93 (83.87%) CXCL5;ATP6V1G1;HLA-DQA1;...
Pathways of neurodegeneration -1.68 3.09e-2 354/475 (74.53%) MAP2K6;ATG101;FZD5;...
Non-alcoholic fatty liver disease -1.70 2.49e-2 126/155 (81.29%) MAPK8;NDUFS3;MAPK11;...
Viral protein interaction with cytokine and cytokine re... -1.70 2.61e-2 84/100 (84%) IL6ST;CX3CL1;IL18R1;...
Lipid and atherosclerosis -1.70 2.68e-2 190/215 (88.37%) PLCB4;CYBB;DDIT3;...
Thermogenesis -1.71 2.81e-2 173/232 (74.57%) NDUFS3;MAPK11;RPS6;...
Drug metabolism -1.71 2.78e-2 78/151 (51.66%) MPO;CYP2C9;UGT2B28;...
Porphyrin and chlorophyll metabolism -1.72 2.94e-2 23/43 (53.49%) UGT2B28;UGT2A3;COX15;...
Coronavirus disease -1.74 2.38e-2 215/232 (92.67%) RPS13;RPS4X;TNF;...
Epithelial cell signaling in Helicobacter pylori infect... -1.78 1.34e-2 62/70 (88.57%) LYN;CDC42;PLCG1;...
Ribosome -1.80 1.20e-2 113/158 (71.52%) RPS29;RPS14;RPL38;...
Renin secretion -1.81 1.20e-2 61/69 (88.41%) PLCB4;NPR1;ADRB2;...
Tyrosine metabolism -1.81 1.30e-2 30/36 (83.33%) AOC3;HGD;GOT2;...
Cardiac muscle contraction -1.81 1.41e-2 64/87 (73.56%) CACNB4;COX7A1;CACNA2D3;...
Mineral absorption -1.86 1.33e-2 48/60 (80%) MT1G;SLC31A1;ATP1B2;...
Proteasome -1.86 1.12e-2 44/46 (95.65%) PSMA3;PSMC6;POMP;...
Amyotrophic lateral sclerosis -1.90 2.50e-3 267/364 (73.35%) MAP2K6;ATG101;SETX;...
Oxidative phosphorylation -1.92 2.81e-3 93/133 (69.92%) ATP6V0E2;NDUFS3;COX6C;...
Retinol metabolism -1.92 3.21e-3 41/68 (60.29%) PNPLA4;BCO1;DGAT1;...
Huntington disease -1.96 1.87e-3 233/306 (76.14%) ATG101;MAPK8;PSMA3;...
Legionellosis -1.98 0.00e+0 51/57 (89.47%) NFKB1;BCL2L13;HSPA2;...
Prion disease -1.99 0.00e+0 209/273 (76.56%) MAPK8;PSMA3;NDUFS3;...
Pyruvate metabolism -2.06 0.00e+0 41/47 (87.23%) FH;ACAT2;ACACB;...
IL-17 signaling pathway -2.06 0.00e+0 84/94 (89.36%) TRAF3IP2;IL17RA;HSP90AA1;...
Parkinson disease -2.54 0.00e+0 176/249 (70.68%) MAPK8;PSMA3;NDUFS3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 15uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H